ClinicalTrials.gg
CompletedNCT04512001Updated Jun 27, 2023Results posted

MSB11456 in Participants With Moderately to Severely Active Rheumatoid Arthritis

A Phase 3 interventional study of MSB11456 and EU-approved RoActemra in Rheumatoid Arthritis, sponsored by Fresenius Kabi SwissBioSim GmbH. Completed at 85 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-06-27.

Sponsored by Fresenius Kabi SwissBioSim GmbH (part of Fresenius Kabi) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
604
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 110 studies testing tocilizumab in Arthritis, Rheumatoid — 5 open to participants now, 5 under way, none of them phase 3. tocilizumab · Arthritis, Rheumatoid.

Enrollment
13th of 110
604 · median 97
Started
2020
with 1 other
Phase 3
65 of 110
none open now
Registered
102nd of 110
by date

Among the 110 studies testing tocilizumab in Arthritis, Rheumatoid, this one is the 13th largest by enrollment, is one of 2 that started in 2020, is one of 65 in phase 3, and was the 102nd registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

5 of the 110 studies testing tocilizumab in Arthritis, Rheumatoid are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About tocilizumab

tocilizumab: first FDA approval 2010 (ACTEMRA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 110 studies testing tocilizumab in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

The purpose of the study is to compare the efficacy, safety and immunogenicity of MSB11456 and EU approved RoActemra® in participants with moderately to severely active rheumatoid arthritis.

Participants will be randomized at the beginning of the Core Treatment Period (Baseline to Week 24) to receive either MSB11456 or EU approved RoActemra® once a week (QW). At the beginning of the Extended Treatment Period (Week 24 to Week 52), participants who received RoActemra® will be re-randomized to either continue receiving RoActemra® QW or switch to receive MSB11456 QW.

03

Conditions studied

  • Rheumatoid Arthritis

Keywords

  • MSB11456
  • RoActemra®
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Are ≥18 years of age.
  • Diagnosis of rheumatoid arthritis according to the revised 1987 ACR/European League Against Rheumatism (EULAR) Classification 2010 criteria with disease duration of ≥6 months.
  • Have moderately to severely active rheumatoid arthritis.
  • Must have been treated with methotrexate for at least 12 consecutive weeks immediately prior to randomization and are on a stable dose between 10 and 25 mg/week methotrexate for the last 8 weeks prior to screening.
  • Have had previous inadequate clinical response to at least one modifying anti-rheumatic drug.
  • Women of (i.e., considered fertile following menarche and until becoming unless permanently sterile) can participate only if they have a negative serum pregnancy test at screening and a negative urine pregnancy test at Day -1 before randomization. Women of childbearing potential must have used and agree to use a highly effective (i.e., methods with a failure rate of less than 1% per year), for 4 weeks before randomization and must agree to continue to practice adequate contraception for 3 months after the last study drug administration.
  • Must voluntarily give written before any study-related activities are performed. Participants must read and fully understand the Informed Consent Form and the requirements of the study. Participants must be willing to comply with all study visits and assessments. Participants must be willing to complete each study procedure. Note: A separate Informed Consent Form (containing important information about COVID 19, clinical research study participation and participant consent) will be provided to and signed by each participant to provide information on the general risks of study participation related to COVID-19 and to document that it is understood by the participant. Another separate Informed Consent Form will be required to be understood and signed by partners of male participating patients who become pregnant during the study or within 10 weeks after the participating patient's last dose of study drug.

Exclusion criteria

Exclusion Criteria:

  • American College of Rheumatology functional class IV as defined by the ACR classification of functional status or wheelchair/bedbound.
  • Previously received tocilizumab, an or licensed biosimilar of tocilizumab or any interleukin-6 acting drugs.
  • Prior use of targeted synthetic disease-modifying anti-rheumatic drugs like janus kinase inhibitors.
  • Prior use of more than 2 biologic treatments for rheumatoid arthritis.
  • Received a live or attenuated vaccine within 4 weeks prior to randomization.
  • Participant is considered by the Investigator, for any reason, to be an unsuitable candidate for the study. Investigator should specifically evaluate the participant's eligibility taking into consideration COVID-19 risk factors and situation.
  • Has a serious and/or unstable and/or poorly controlled medical condition such as but not limited to poorly controlled diabetes, unstable ischemic heart disease, uncontrolled hypertension or other cardiovascular, cerebrovascular, cardiovascular, gastrointestinal disease, hepatic, renal, hematological, endocrine, nervous system or pulmonary disease or other relevant medical condition or a history of disease or any other condition that, in the opinion of the Investigator, would put the participant at risk by participation in the study.
  • Confirmed or, based on the signs and symptoms observed at the time of assessment, suspected active COVID-19 infection at the time of screening and/or randomization.
  • Has had any infection as follows:

    1. Herpes zoster or any opportunistic invasive infection within 6 months of screening.
    2. Frequent, chronic or recurrent infections.
    3. A positive test for subtype 1 (HIV-1) or 2 (HIV-2), antibody, surface antigen and/or core antibody for immunoglobulin G and/or immunoglobulin M or total immunoglobulin at screening.
    4. A serious infection within 8 weeks prior to randomization.
    5. Required treatment with oral antibiotics and/or anti-fungal drugs within 14 days prior to randomization.
  • Medical evidence of active or latent tuberculosis as indicated by a positive QuantiFERON®-TB Gold Plus test, chest X-ray and/or clinical examination or has had active or latent tuberculosis disease at any time in the past.
  • Received a COVID 19 vaccine within 4 weeks prior to randomization, are receiving ongoing COVID-19 vaccination at the time of screening or plan to receive COVID-19 vaccination before the completion of the Week 30 visit of the study. COVID-19 vaccination is considered ongoing if a multidose regimen has been started but has not been completed.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
604 participants (actual)

Study arms

  • Experimental
    MSB11456

    Drug: MSB11456

  • Active comparator
    RoActemra®

    Drug: EU-approved RoActemra

Interventions

  • Participants will receive MSB11456 subcutaneously, once a week.

  • DrugEU-approved RoActemra

    Participants will receive EU-approved RoActemra® subcutaneously, once a week.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Disease Activity Score 28-Erythrocyte Sedimentation Rate (DAS28-ESR)

    The DAS28-ESR is a measure of disease activity in 28 joints that consists of a composite numerical score of the following variables: Tender Joint Count (TJC), Swollen Joint Count (SJC), erythrocyte sedimentation rate (ESR) and Patient's Global Assessment of Disease Activity. The DAS28-ESR score was derived using the formula: DAS28-ESR = 0.56\*√(TJC28) + 0.28\*√(SJC28) + 0.014\*GH + 0.70\*Ln(ESR), where, TJC28 = 28 joint count for tenderness, SJC28 = 28 joint count for swelling, Ln(ESR) = natural logarithm of ESR, GH = the general health component of the DAS (i.e., Patient's Global Assessment of Disease Activity on a scale of 1 to 100 where 100 is maximal activity). Higher values mean a higher disease activity. The level of disease activity can be interpreted as: * Remission (score of \<2.6). * Low (score of ≤2.6 to \<3.2). * Moderate (score of ≤3.2 to ≤5.1). * High (score of \>5.1) A negative change from baseline indicates an improvement.

    Time frame: Baseline; Week 24

Secondary outcomes

  1. Change From Baseline in Disease Activity Score 28-Erythrocyte Sedimentation Rate (DAS28-ESR)

    The DAS28-ESR is a measure of disease activity in 28 joints that consists of a composite numerical score of the following variables: TJC, SJC, ESR and Patient's Global Assessment of Disease Activity. The DAS28-ESR score was derived using the formula: DAS28-ESR = 0.56\*√(TJC28) + 0.28\*√(SJC28) + 0.014\*GH + 0.70\*Ln(ESR), where, TJC28 = 28 joint count for tenderness, SJC28 = 28 joint count for swelling, Ln(ESR) = natural logarithm of ESR, GH = the general health component of the DAS (i.e., Patient's Global Assessment of Disease Activity on a scale of 1 to 100 where 100 is maximal activity). Higher values mean a higher disease activity. The level of disease activity can be interpreted as: * Remission (score of \<2.6). * Low (score of ≤2.6 to \<3.2). * Moderate (score of ≤3.2 to ≤5.1). * High (score of \>5.1) A negative change from baseline indicates an improvement. For weeks 30, 42 and 52, the extended baseline (week 24) was used for the change in DAS28-ESR calculation.

    Time frame: Baseline, Week 2, Week 4, Week 8, Week 12, Week 16; Extended Period Baseline (Week 24), Week 30, Week 42, and Week 52

  2. Number of Participants With 20% Improvement in American College of Rheumatology (ACR20) Response

    ACR20 was defined as the number of participants with at least 20% improvement from baseline in number of tender and swollen joints (68/66 joint count), and at least 20% improvement from baseline in three or more of the 5 ACR Core Set measures: * Patient's Assessment of Arthritis Pain * Physical Function Assessment (Health Assessment Questionnaire-Disability Index) * Acute phase reactant level (erythrocyte sedimentation rate or C-reactive protein) * Patient's Global Assessment of Disease Activity and * Physician's Global Assessment of Disease Activity

    Time frame: Baseline; Week 24

  3. Number of Participants Who Experienced One or More Treatment-Emergent Adverse Event (TEAE)

    Time frame: Baseline to end of study, up to Week 63

  4. Number of Participants Who Experienced One or More Treatment-Emergent Serious Adverse Event (TESAE)

    Time frame: Baseline to end of study, up to Week 63

  5. Percentage of Participants With Positive Anti-Drug Antibodies (ADAs)

    Time frame: Baseline, Week 2, Week 12, Week 24, Week 30, Week 52 and Week 55

  6. Anti-Drug Antibodies (ADAs) Titer Levels

    Time frame: Baseline, Week 2, Week 12, Week 24, Week 30, Week 52 and Week 55

  7. Percentage of Participants With Neutralizing Antibodies (NAb)

    Time frame: Baseline, Week 2, Week 12, Week 24, Week 30, Week 52 and Week 55

07

Results

Posted Oct 24, 2022

Participant flow

Week 0 to Week 24
Participant flow — Week 0 to Week 24
MilestoneCore Treatment Period: MSB11456Core Treatment Period: RoActemra®Core Treatment Period: MSB11456; Extended Treatment Period: MSB11456Core Treatment Period: RoActemra®; Extended Treatment Period: MSB11456Core Treatment Period: EU-approved RoActemra®; Extended Treatment Period: EU-approved RoActemra®
Started302302000
Received treatment302302000
Completed267276000
Not completed3526000
Withdrew: Adverse event1410000
Withdrew: Death02000
Withdrew: Withdrawal by subject169000
Withdrew: Discontinued treatment prior to week 2444000
Withdrew: Withdrawal by sponsor's decision10000
Withdrew: Subject did not meet eligibility but was randomized01000
Week 24 to Week 63
Participant flow — Week 24 to Week 63
MilestoneCore Treatment Period: MSB11456Core Treatment Period: RoActemra®Core Treatment Period: MSB11456; Extended Treatment Period: MSB11456Core Treatment Period: RoActemra®; Extended Treatment Period: MSB11456Core Treatment Period: EU-approved RoActemra®; Extended Treatment Period: EU-approved RoActemra®
Started00267139137
Received treatment00266139136
Completed00244123122
Not completed00231615
Withdrew: Adverse event001386
Withdrew: Lost to follow-up00111
Withdrew: Death00011
Withdrew: Withdrawal by subject00646
Withdrew: Miscellaneous00321

Outcome measures

PrimaryChange From Baseline in Disease Activity Score 28-Erythrocyte Sedimentation Rate (DAS28-ESR)

The DAS28-ESR is a measure of disease activity in 28 joints that consists of a composite numerical score of the following variables: Tender Joint Count (TJC), Swollen Joint Count (SJC), erythrocyte sedimentation rate (ESR) and Patient's Global Assessment of Disease Activity. The DAS28-ESR score was derived using the formula: DAS28-ESR = 0.56\*√(TJC28) + 0.28\*√(SJC28) + 0.014\*GH + 0.70\*Ln(ESR), where, TJC28 = 28 joint count for tenderness, SJC28 = 28 joint count for swelling, Ln(ESR) = natural logarithm of ESR, GH = the general health component of the DAS (i.e., Patient's Global Assessment of Disease Activity on a scale of 1 to 100 where 100 is maximal activity). Higher values mean a higher disease activity. The level of disease activity can be interpreted as: * Remission (score of \<2.6). * Low (score of ≤2.6 to \<3.2). * Moderate (score of ≤3.2 to ≤5.1). * High (score of \>5.1) A negative change from baseline indicates an improvement.

Time frame:
Baseline; Week 24
Reported as:
Least squares mean · score on a scale
Change From Baseline in Disease Activity Score 28-Erythrocyte Sedimentation Rate (DAS28-ESR)
score on a scaleCore Treatment Period: MSB11456Core Treatment Period: RoActemra®
Change From Baseline in Disease Activity Score 28-Erythrocyte Sedimentation Rate (DAS28-ESR)-3.53 ± 0.106-3.54 ± 0.106
Statistical analysis
  • Core Treatment Period: MSB11456 vs Core Treatment Period: RoActemra® · Least squares means difference: 0.01 · 90% CI -0.16 to 0.18
SecondaryChange From Baseline in Disease Activity Score 28-Erythrocyte Sedimentation Rate (DAS28-ESR)

The DAS28-ESR is a measure of disease activity in 28 joints that consists of a composite numerical score of the following variables: TJC, SJC, ESR and Patient's Global Assessment of Disease Activity. The DAS28-ESR score was derived using the formula: DAS28-ESR = 0.56\*√(TJC28) + 0.28\*√(SJC28) + 0.014\*GH + 0.70\*Ln(ESR), where, TJC28 = 28 joint count for tenderness, SJC28 = 28 joint count for swelling, Ln(ESR) = natural logarithm of ESR, GH = the general health component of the DAS (i.e., Patient's Global Assessment of Disease Activity on a scale of 1 to 100 where 100 is maximal activity). Higher values mean a higher disease activity. The level of disease activity can be interpreted as: * Remission (score of \<2.6). * Low (score of ≤2.6 to \<3.2). * Moderate (score of ≤3.2 to ≤5.1). * High (score of \>5.1) A negative change from baseline indicates an improvement. For weeks 30, 42 and 52, the extended baseline (week 24) was used for the change in DAS28-ESR calculation.

Time frame:
Baseline, Week 2, Week 4, Week 8, Week 12, Week 16; Extended Period Baseline (Week 24), Week 30, Week 42, and Week 52
Reported as:
Mean · score on a scale
Change From Baseline in Disease Activity Score 28-Erythrocyte Sedimentation Rate (DAS28-ESR)
score on a scaleCore Treatment Period: MSB11456Core Treatment Period: RoActemra®Core Treatment Period: MSB11456; Extended Treatment Period: MSB11456Core Treatment Period: RoActemra®; Extended Treatment Period: MSB11456Core Treatment Period: EU-approved RoActemra®; Extended Treatment Period: EU-approved RoActemra®
Week 2-1.24 ± 1.022-1.21 ± 0.949———
Week 4-1.96 ± 1.184-1.98 ± 1.135———
Week 8-2.75 ± 1.220-2.69 ± 1.260———
Week 12-3.13 ± 1.249-3.09 ± 1.279———
Week 16-3.41 ± 1.288-3.32 ± 1.242———
Week 30——-0.16 ± 0.801-0.13 ± 0.756-0.02 ± 0.863
Week 42——-0.34 ± 1.042-0.08 ± 1.026-0.27 ± 1.031
Week 52——-0.42 ± 1.185-0.31 ± 1.064-0.37 ± 1.086
SecondaryNumber of Participants With 20% Improvement in American College of Rheumatology (ACR20) Response

ACR20 was defined as the number of participants with at least 20% improvement from baseline in number of tender and swollen joints (68/66 joint count), and at least 20% improvement from baseline in three or more of the 5 ACR Core Set measures: * Patient's Assessment of Arthritis Pain * Physical Function Assessment (Health Assessment Questionnaire-Disability Index) * Acute phase reactant level (erythrocyte sedimentation rate or C-reactive protein) * Patient's Global Assessment of Disease Activity and * Physician's Global Assessment of Disease Activity

Time frame:
Baseline; Week 24
Reported as:
Count of participants · Participants
Number of Participants With 20% Improvement in American College of Rheumatology (ACR20) Response
ParticipantsCore Treatment Period: MSB11456Core Treatment Period: RoActemra®
Number of Participants With 20% Improvement in American College of Rheumatology (ACR20) Response244256
Statistical analysis
  • Core Treatment Period: MSB11456 vs Core Treatment Period: RoActemra® · Difference in % response rate: -3.94 · 95% CI -9.97 to 2.11
SecondaryNumber of Participants Who Experienced One or More Treatment-Emergent Adverse Event (TEAE)
Time frame:
Baseline to end of study, up to Week 63
Reported as:
Count of participants · Participants
Number of Participants Who Experienced One or More Treatment-Emergent Adverse Event (TEAE)
ParticipantsMSB11456Core Treatment Period: RoActemra®; Extended Treatment Period: MSB11456EU-approved RoActemra®
Number of Participants Who Experienced One or More Treatment-Emergent Adverse Event (TEAE)237105125
SecondaryNumber of Participants Who Experienced One or More Treatment-Emergent Serious Adverse Event (TESAE)
Time frame:
Baseline to end of study, up to Week 63
Reported as:
Count of participants · Participants
Number of Participants Who Experienced One or More Treatment-Emergent Serious Adverse Event (TESAE)
ParticipantsMSB11456Core Treatment Period: RoActemra®; Extended Treatment Period: MSB11456EU-approved RoActemra®
Number of Participants Who Experienced One or More Treatment-Emergent Serious Adverse Event (TESAE)512033
SecondaryPercentage of Participants With Positive Anti-Drug Antibodies (ADAs)
Time frame:
Baseline, Week 2, Week 12, Week 24, Week 30, Week 52 and Week 55
Reported as:
Number · percentage of participants
Percentage of Participants With Positive Anti-Drug Antibodies (ADAs)
percentage of participantsCore Treatment Period: MSB11456Core Treatment Period: RoActemra®Core Treatment Period: MSB11456; Extended Treatment Period: MSB11456Core Treatment Period: RoActemra®; Extended Treatment Period: MSB11456Core Treatment Period: EU-approved RoActemra®; Extended Treatment Period: EU-approved RoActemra®
Overall (includes all time points expect Baseline)96.096.397.497.194.1
Baseline6.68.3———
Week 287.188.7———
Week 1279.074.3———
Week 24 (Extended Treatment Period Baseline)76.368.686.877.787.5
Week 30——76.773.165.9
Week 52——80.976.861.1
Week 55——81.482.877.9
SecondaryAnti-Drug Antibodies (ADAs) Titer Levels
Time frame:
Baseline, Week 2, Week 12, Week 24, Week 30, Week 52 and Week 55
Reported as:
Geometric mean · titer
Anti-Drug Antibodies (ADAs) Titer Levels
titerCore Treatment Period: MSB11456Core Treatment Period: RoActemra®Core Treatment Period: MSB11456; Extended Treatment Period: MSB11456Core Treatment Period: RoActemra®; Extended Treatment Period: MSB11456Core Treatment Period: EU-approved RoActemra®; Extended Treatment Period: EU-approved RoActemra®
Overall (includes all time points except Baseline)106.3 (60 to 15360)104.0 (60 to 122880)215.4 (60 to 15360)166.3 (60 to 15360)101.1 (60 to 960)
Baseline71.4 (60 to 960)130.4 (60 to 1920)———
Week 281.2 (60 to 1920)88.1 (60 to 15360)———
Week 12113.8 (60 to 960)123.1 (60 to 122880)———
Week 24 (Extended Treatment Period Baseline)138.4 (60 to 15360)102.9 (60 to 1920)127.7 (60 to 15360)106.1 (60 to 1920)95.6 (60 to 960)
Week 30——173.0 (60 to 15360)130.6 (60 to 7680)93.7 (60 to 960)
Week 52——230.9 (60 to 7680)174.7 (60 to 15360)96.7 (60 to 480)
Week 55——251.2 (60 to 15360)200.8 (60 to 15360)112.4 (60 to 480)
SecondaryPercentage of Participants With Neutralizing Antibodies (NAb)
Time frame:
Baseline, Week 2, Week 12, Week 24, Week 30, Week 52 and Week 55
Reported as:
Number · percentage of participants
Percentage of Participants With Neutralizing Antibodies (NAb)
percentage of participantsCore Treatment Period: MSB11456Core Treatment Period: RoActemra®Core Treatment Period: MSB11456; Extended Treatment Period: MSB11456Core Treatment Period: RoActemra®; Extended Treatment Period: MSB11456Core Treatment Period: EU-approved RoActemra®; Extended Treatment Period: EU-approved RoActemra®
Overall (includes all time points except Baseline)8.411.313.216.811.9
Baseline00———
Week 23.83.4———
Week 122.54.1———
Week 24 (Extended Treatment Period Baseline)2.94.93.85.85.9
Week 30——6.19.73.0
Week 52——1.62.41.6
Week 55——7.06.69.0

Adverse events

Collected over Day 1 up to Week 63. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
MSB114560/302 (0%)51/302 (16.9%)163/302 (54%)
Core Treatment Period: RoActemra®; Extended Treatment Period: MSB114561/139 (0.7%)20/139 (14.4%)82/139 (59%)
EU-approved RoActemra®3/163 (1.8%)33/163 (20.2%)92/163 (56.4%)
Most frequent serious events
Showing 10 of 50
Most frequent serious events
EventMSB11456Core Treatment Period: RoActemra®; Extended Treatment Period: MSB11456EU-approved RoActemra®
COVID-19Infections and infestations38/30212/13919/163
Myocardial infarctionCardiac disorders1/3021/1390/163
Carotid artery diseaseNervous system disorders0/3021/1390/163
CholecystitisHepatobiliary disorders0/3021/1390/163
CholelithiasisHepatobiliary disorders0/3021/1390/163
Wrist fractureInjury, poisoning and procedural complications0/3021/1390/163
Bacterial infectionInfections and infestations0/3021/1390/163
Pelvic inflammatory diseaseInfections and infestations0/3021/1390/163
Arteriosclerosis coronary arteryCardiac disorders0/3021/1390/163
OsteoarthritisMusculoskeletal and connective tissue disorders0/3021/1390/163
Most frequent other events
Showing 10 of 33
Most frequent other events
EventMSB11456Core Treatment Period: RoActemra®; Extended Treatment Period: MSB11456EU-approved RoActemra®
Alanine aminotransferase increasedInvestigations36/30222/13922/163
COVID-19Infections and infestations38/30212/13919/163
LeukopeniaBlood and lymphatic system disorders22/3028/13912/163
Aspartate aminotransferase increasedInvestigations19/3029/13910/163
NeutropeniaBlood and lymphatic system disorders19/3028/13910/163
Upper respiratory tract infectionInfections and infestations17/3026/13910/163
Blood bilirubin increasedInvestigations11/3028/1393/163
HeadacheNervous system disorders17/3022/1394/163
NasopharyngitisInfections and infestations9/3025/1399/163
Mycobacterium tuberculosis complex test positiveInvestigations14/3024/1394/163

Baseline characteristics

The Intent-To-Treat (ITT) Analysis Set: includes all randomized participants.

Age, Continuous
Age, Continuous(years)Core Treatment Period: MSB11456Core Treatment Period: RoActemra®Total
Mean51.2 ± 12.7253.2 ± 11.3352.2 ± 12.08
Sex: Female, Male
Sex: Female, Male(Participants)Core Treatment Period: MSB11456Core Treatment Period: RoActemra®Total
Female250248498
Male5254106
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Core Treatment Period: MSB11456Core Treatment Period: RoActemra®Total
Hispanic or Latino123
Not Hispanic or Latino300300600
Unknown or Not Reported101
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Core Treatment Period: MSB11456Core Treatment Period: RoActemra®Total
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American000
White302302604
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)Core Treatment Period: MSB11456Core Treatment Period: RoActemra®Total
Hungary192342
Czechia192544
Poland156147303
Moldova14923
Georgia435194
Slovakia516
Bulgaria181634
Serbia71118
Russia211940
08

Study locations

85 sites
  • Medical Center Hipokrat 2000 OOD
    Haskovo, Khaskovo 6300, Bulgaria
  • MHAT "Lyulin" EAD
    Sofia, Sofiya 1336, Bulgaria
  • Military Medical Academy - Sofia
    Sofia, Sofiya 1606, Bulgaria
  • Medical Center N.I.Pirogov EOOD
    Sofia, Sofiya 1612, Bulgaria
  • Medical Center MedConsult Pleven
    Pleven, 5800, Bulgaria
  • University Multiprofile Hospital for Active Treatment Pulmed
    Plovdiv, 4002, Bulgaria
  • Multiprofile Hospital for Active Treatment Plovdiv
    Plovdiv, 4003, Bulgaria
  • Medical Center Teodora
    Ruse, 7012, Bulgaria
  • Diagnostic and Consultative Center Equita
    Varna, 9002, Bulgaria
  • MC Sanador M
    Vidin, 3703, Bulgaria
  • Revmatologie, s.r.o.
    Brno, Jihormoravsky KRAJ 638 00, Czechia
  • Medical Plus
    Uherské Hradiště, Jihormoravsky KRAJ 686 01, Czechia
  • Revmatologie MUDr. Zuzana Urbanova
    Praha 4, Praha 140 00, Czechia
  • CCR Ostrava
    Ostrava, Severomoravsky KRAJ 702 00, Czechia
  • Revmatologie MUDr. Klára Šírová s.r.o.
    Ostrava, Severomoravsky KRAJ 702 00, Czechia
  • PV-Medical Services, s.r.o.
    Zlin, Severomoravsky KRAJ 760 01, Czechia
  • Vesalion s.r.o.
    Ostrava, 702 00, Czechia
  • Revmatologicky Ustav
    Praha, 128 50, Czechia
  • Helsicore - Israeli Georgian Medical Research Clinic
    Tbilisi, 0112, Georgia
  • Research Institute of Clinical Medicine
    Tbilisi, 0112, Georgia
  • The First University Clinic
    Tbilisi, 0141, Georgia
  • EVEX Hospitals - Caraps Medline
    Tbilisi, 0159, Georgia
  • Tbilisi Heart and Vascular Clinic
    Tbilisi, 0159, Georgia
  • MediClub Georgia
    Tbilisi, 0160, Georgia
  • Georgian Dutch Hospital Ltd
    Tbilisi, 0172, Georgia
  • Mtskheta Street Clinic
    Tbilisi, 0179, Georgia
  • Tbilisi Heart Center
    Tbilisi, 0186, Georgia
  • Szegedi Tudomanyegyetem Szent-Gyorgyi Albert Klinikai Kozpont
    Szeged, Csongrad 6725, Hungary
  • Csongrad Megyei Dr. Bugyi Istvan Korhaz
    Szentes, Csongrad 6600, Hungary
  • DRC Gyogyszervizsgalo Kozpont Kft.
    Szekesfehervar, Fejer 8000, Hungary
  • SALDINVEST Befektetesi es Vagyonkezelo Korlatolt Felelossegu Tarsasag
    Szekesfehervar, Fejer 8000, Hungary
  • Integrity Gyogyaszati Kozpont
    Zalaegerszeg, Zala 8900, Hungary
  • Revita Reumatologiai Rendelo
    Budapest, 1027, Hungary
  • MÁV Kórház és Rendelőintézet Rheumatológia
    Szolnok, 5000, Hungary
  • Vital Medical Center Orvosi es Fogaszati Kozpont
    Veszprem, 8200, Hungary
  • Institutia Medico-Sanitara Publica Institutul de Cardiologie
    Chisinau, 2025, Moldova, Republic of
  • Spitalul Clinic Republican
    Chisinau, 2025, Moldova, Republic of
  • IMSP Spitalul Clinic Municipal Sfanta Treime
    Chisinau, 2068, Moldova, Republic of
  • Instituţia Medico-Sanitară Publică Institutul de Cardiologie
    Chisinau, MD 2025, Moldova, Republic of
  • WroMedica
    Wroclaw, Dolnoslaskie 51-685, Poland
  • Centrum Medyczne Oporow
    Wroclaw, Dolnoslaskie 52-416, Poland
  • Nasz Lekarz Osrodek Badan Klinicznych - Bydgoszcz
    Bydgoszcz, Kujawsko-pomorskie 85-068, Poland
  • Nasz Lekarz Przychodnie Medyczne
    Torun, Kujawsko-pomorskie 87-100, Poland
  • Centrum Terapii Wspolczesnej
    Lodz, Lodzkie 90-242, Poland
  • TRIALMED CRS Piotrków Trybunalski
    Piotrków Trybunalski, Lodzkie 97-300, Poland
  • Samodzielny Publiczny Zespol Opieki Zdrowotnej w Tomaszow Lubelski
    Tomaszow Lubelski, Lubelskie 22-600, Poland
  • Twoja Przychodnia-Centrum Medyczne Nowa Sol
    Nowa Sol, Lubuskie 67-100, Poland
  • Grazyna Pulka Specjalistyczny Osrodek All-med
    Krakow, Malopolskie 30-033, Poland
  • Pratia MCM Krakow
    Krakow, Malopolskie 30-510, Poland
  • RCMed Oddzial Sochaczew
    Sochaczew, Mazowieckie 96-500, Poland
  • Medycyna Kliniczna
    Warszawa, Mazowieckie 00-874, Poland
  • Rheuma Medicus Zaklad Opieki Zdrowotnej
    Warszawa, Mazowieckie 02-118, Poland
  • Ars Rheumatica - Reumatika Centrum Reumatologii
    Warszawa, Mazowieckie 02-691, Poland
  • Barwijuk Clinics
    Warszawa, Mazowieckie 02-884, Poland
  • Centrum Medyczne AMED Warszawa Targowek
    Warszawa, Mazowieckie 03-291, Poland
  • SANUS Szpital Specjalistyczny
    Stalowa Wola, Podkarpackie 37-450, Poland
  • Osteo-Medic
    Bialystok, Podlaskie 15-351, Poland
  • ClinicMed Daniluk Nowak Spolka Jawna
    Bialystok, Podlaskie 15-879, Poland
  • Centrum Medyczne Pratia w Gdyni
    Gdynia, Pomorskie 81-338, Poland
  • Silmedic w Swidniku
    Katowice, Slaskie 40-282, Poland
  • Ambulatorium Sp. z
    Elblag, Warminsko-mazurskie 82-300, Poland
  • Centrum Kliniczno Badawcze J Brzezicki B Gornikiewicz Brzezicka Lekarze Spolka Partnerska
    Elblag, Warminsko-mazurskie 82-300, Poland
  • Solumed Centrum Medyczne
    Poznan, Wielkopolskie 60-529, Poland
  • Centrum Badan Klinicznych S.C.
    Poznan, Wielkopolskie 60-773, Poland
  • Ai Centrum Medyczne
    Poznan, Wielkopolskie 61-113, Poland
  • Centrum Medyczne HCP
    Poznan, Wielkopolskie 61-485, Poland
  • Clinical Rheumatological Hospital Number 25
    Saint-Petersburg, Saint Petersburg 190068, Russian Federation
  • Kazan State Medical University
    Kazan, Tatarstan 420103, Russian Federation
  • State Budgetary Healthcare Institution of the Yaroslavl Region Clinical Hospital No. 2
    Yaroslavl, Yaroslavlr 150023, Russian Federation
  • Chelyabinsk Regional Clinical Hospital
    Chelyabinsk, 454076, Russian Federation
  • CjSC "Center of Family Medicine"
    Ekaterinburg, 620043, Russian Federation
  • Medical Center Revma-Med
    Kemerovo, 650070, Russian Federation
  • NIARMEDIK - Clinic on Clinic on Kitai Gorod
    Moscow, 101000, Russian Federation
  • Medical Center Health Family
    Novosibirsk, 630099, Russian Federation
  • Polyclinic of Private Security Personnel
    Saint Petersburg, 192007, Russian Federation
  • Saratov Regional Clinical Hospital
    Saratov, 410053, Russian Federation
  • Departmental Hospital at Smolensk Station of JSC RZhD
    Smolensk, 214025, Russian Federation
  • Biomed
    Vladimir, 600005, Russian Federation
  • Institute of Rheumatology
    Belgrade, 11000, Serbia
  • Institut za Lecenje i Rehabilitaciju Niška Banja
    Niška Banja, 18205, Serbia
  • Specijalna Bolnica za Reumatske bolesti Novi Sad
    Novi Sad, 21112, Serbia
  • General Hospital Djordje Jovanovic Zrenjanin
    Zrenjanin, 23000, Serbia
  • REUMEX s.r.o.
    Rimavska Sobota, 979 01, Slovakia
  • LERAM s.r.o.
    Topolcany, 95501, Slovakia
  • ALBAMED s.r.o.
    Zvolen, 960 01, Slovakia
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2020 to primary completion in Aug 2021, 12 months.

Results were first posted in Oct 2022, 1 year 1 month after primary completion.

Of 116 industry-sponsored phase 3 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 31. This study's 12 months is below that.

Counting every sponsor, half of 148 studies reached it within 26 months; a quarter within 17 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 11, 2020
First posted
Aug 13, 2020
StartActual
Aug 3, 2020
Primary completionActual
Aug 31, 2021
CompletionActual
Jun 6, 2022
Results first posted
Oct 24, 2022
Last update
Jun 27, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 27, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04512001
Responsible party
Sponsor
First posted
Aug 13, 2020
Start date
Aug 3, 2020
Primary completion
Aug 31, 2021
Completion
Jun 6, 2022
Results posted
Oct 24, 2022
Last update
Jun 27, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tocilizumab

Start the discussion